CALCIJEX Drug Patent Profile

✉ Email this page to a colleague

When do Calcijex patents expire, and when can generic versions of Calcijex launch?

Calcijex is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in CALCIJEX is calcitriol. There are ten drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the calcitriol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Calcijex

A generic version of CALCIJEX was approved as calcitriol by TEVA on October 12^th, 2001.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for CALCIJEX?
What are the global sales for CALCIJEX?
What is Average Wholesale Price for CALCIJEX?

Summary for CALCIJEX

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	90
Clinical Trials:	5
Patent Applications:	4,220
DailyMed Link:	CALCIJEX at DailyMed

Drug patent expirations by year for CALCIJEX

Recent Clinical Trials for CALCIJEX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Roswell Park Cancer Institute	Phase 1
National Cancer Institute (NCI)	Phase 1
Statistika Consultoria Ltda	Phase 4

See all CALCIJEX clinical trials

US Patents and Regulatory Information for CALCIJEX

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	CALCIJEX	calcitriol	INJECTABLE;INJECTION	018874-001	Sep 25, 1986		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Abbvie	CALCIJEX	calcitriol	INJECTABLE;INJECTION	018874-002	Sep 25, 1986		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for CALCIJEX

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	CALCIJEX	calcitriol	INJECTABLE;INJECTION	018874-001	Sep 25, 1986	⤷ Sign Up	⤷ Sign Up
Abbvie	CALCIJEX	calcitriol	INJECTABLE;INJECTION	018874-001	Sep 25, 1986	⤷ Sign Up	⤷ Sign Up
Abbvie	CALCIJEX	calcitriol	INJECTABLE;INJECTION	018874-001	Sep 25, 1986	⤷ Sign Up	⤷ Sign Up
Abbvie	CALCIJEX	calcitriol	INJECTABLE;INJECTION	018874-002	Sep 25, 1986	⤷ Sign Up	⤷ Sign Up
Abbvie	CALCIJEX	calcitriol	INJECTABLE;INJECTION	018874-002	Sep 25, 1986	⤷ Sign Up	⤷ Sign Up
Abbvie	CALCIJEX	calcitriol	INJECTABLE;INJECTION	018874-002	Sep 25, 1986	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for CALCIJEX

See the table below for patents covering CALCIJEX around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Canada	1174605	PREPARATION AQUEUSE, DILUEE ET STABILISEE, A BASE DE 1.alpha., 25-DIHYDROXYCHOLECALCIFEROL POUR ADMINISTRATION NEONATALE (STABILIZED, DILUTE AQUEOUS PREPARATION OF 1.alpha., 25- DIHYDROXYCHOLECALCIFEROL FOR NEONATAL ADMINISTRATION)	⤷ Sign Up
United Kingdom	2091556	AQUEOUS PREPARATION OF 1A 25-DIHYDROXYCHOLECALCIFEROL	⤷ Sign Up
France	2126414		⤷ Sign Up
Germany	3202622		⤷ Sign Up
Australia	549765		⤷ Sign Up
New Zealand	199472	STABILISED PHARMACEUTICAL COMPOSITION OF 1, 25-DIHYDROXYCHOLECALCIFEROL	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for CALCIJEX

Recent Clinical Trials for CALCIJEX

Make Better Decisions: Try a trial or see plans & pricing